Baillie Gifford & CO Denali Therapeutics Inc. Transaction History
Baillie Gifford & CO
- $128 Billion
- Q3 2025
A detailed history of Baillie Gifford & CO transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 11,591,585 shares of DNLI stock, worth $189 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
11,591,585
Previous 11,955,323
3.04%
Holding current value
$189 Million
Previous $167 Million
0.63%
% of portfolio
0.13%
Previous 0.13%
Shares
32 transactions
Others Institutions Holding DNLI
# of Institutions
251Shares Held
134MCall Options Held
148KPut Options Held
15.4K-
Black Rock Inc. New York, NY13.2MShares$214 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$192 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.58MShares$107 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL6.26MShares$102 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA5.66MShares$92.2 Million0.01% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.18B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...